BioSpace News Archive

The drive for generic injectables has risen on the back of the recent fillip received by the generic pharmaceutical industry, fueled by the nearing patent expiry of several blockbuster drugs.

Barrett’s esophagus is one of the major complications of gastro-esophageal reflux disease in which the normal squamous tissue lining the esophagus changes to the tissue resembling that of the intestine lining.

Orphazyme A/S has introduced a modified long-term incentive program for 2021 with the view to retaining members of the Executive Management and other employees of the Group, while also creating an incentive for a positive share price development and corporate performance for the benefit of the Company’s shareholders.

The Xlife-project company inflamed pharma GmbH has concluded an exclusive license agreement with the Austrian Vitesse Trading GmbH for the sale of its active ingredient ProcCluster.

Sapreme, a biotechnology company focused on improving the delivery and efficacy of macromolecule therapeutics, announced that it has closed a EUR 15 million Series A financing round to accelerate the buildout of its endosomal escape technology platform and support the further progress of its proprietary pipeline and corporate development activities.

CytoDyn Inc. announced today the filing of a complaint for declaratory and injunctive relief and motion for a preliminary injunction against NSF International, Inc. and its subsidiary Amarex Clinical Research (“Amarex”), the Company’s former Contract Research Organization (“CRO”).

CytoDyn Inc., a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced a study for treating triple-negative breast cancer with leronlimab in a humanized TNBC xenograft model.

IONIQ Sciences, Inc., is developing a rapid and non-invasive Multi-Cancer Screen for early detection that has the potential to expand the therapeutic window, dramatically improve survivability and reduce the cost of healthcare.

ProMIS Neurosciences Inc., a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, is pleased to announce that it will hold a special general meeting of shareholders on December 1, 2021.

Turning Point Therapeutics, Inc. today announced the presentation of additional preliminary clinical data from ongoing trials for lead drug candidate repotrectinib, and elzovantinib (TPX-0022), a novel MET/SRC/CSF1R inhibitor.